- COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status2017 | Lékařská fakulta v Hradci Králové
- External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score2021 | Lékařská fakulta v Hradci Králové, 3. lékařská fakulta
- Refining prognosis after first-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy in chronic lymphocytic leukaemia2019 | Lékařská fakulta v Hradci Králové
- Moderní přístup k léčbě chronické lymfocytární leukemie2023 | Lékařská fakulta v Hradci Králové
- Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia2017 | 3. lékařská fakulta
- Profiling of biological and environmental risk factors in immunogenetic subgroups of chronic lymphocytic leukemia - Czech national study2020 | 1. lékařská fakulta
- Frontline treatment with the combination obinutuzumab +/- chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group2020 | Lékařská fakulta v Hradci Králové, 1. lékařská fakulta
- Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group2021 | Lékařská fakulta v Hradci Králové, Ústřední knihovna
- Practical approach to management of chronic lymphocytic leukemia2016 | Lékařská fakulta v Hradci Králové
- Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study2023 | Publikace bez příslušnosti k fakultě
- Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study2018 | Publikace bez příslušnosti k fakultě
- Deciphering the complex circulating immune cell microenvironment in chronic lymphocytic leukaemia using patient similarity networks2021 | Lékařská fakulta v Hradci Králové, 3. lékařská fakulta, 1. lékařská fakulta
- Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia2021 | Lékařská fakulta v Hradci Králové, 3. lékařská fakulta
- Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial2017 | Lékařská fakulta v Hradci Králové
- Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?2021 | Lékařská fakulta v Hradci Králové
- Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial2023 | Lékařská fakulta v Hradci Králové